川芎嗪对不稳定型心绞痛患者血浆超敏C反应蛋白和脂蛋白相关磷脂酶A2的影响

发布时间：2018-03-20 00:35

本文选题：不稳定型心绞痛　切入点：川芎嗪　出处：《辽宁中医杂志》2017年07期 　论文类型：期刊论文

【摘要】：目的:探讨川芎嗪对不稳定型心绞痛患者血浆超敏C反应蛋白和脂蛋白相关磷脂酶A2的影响。方法:将2016年1月—2016年10月在本院心内科治疗的100例不稳定型心绞痛患者随机分为两组,对照组50例采用常规治疗方法,在此基础上观察组50例加用川芎嗪注射液治疗,比较两组患者的治疗效果、发病频率和发病时间、各项实验室指标情况。结果:观察组用药后治疗有效率为94%,显著高于对照组的78%,差异有统计学意义(P0.05);观察组治疗后心绞痛发作次数及心绞痛持续时间均明显较对照组减少,差异有统计学意义(P0.05);观察组治疗后血浆超敏C反应蛋白(hs-CRP)、脂蛋白相关磷脂酶A2(Lp-PLA2)、心肌肌钙蛋白I(cTnI)明显较对照组降低,差异有统计学意义(P0.05)。结论:川芎嗪对不稳定型心绞痛患者治疗效果显著,能有效减少心绞痛的发作,降低炎症反应对心肌损伤,提高心肌修复能力,具有积极的临床意义。
[Abstract]:Objective: to investigate the effect of ligustrazine on plasma hypersensitive C-reactive protein and lipoprotein associated phospholipase A2 in patients with unstable angina pectoris. Patients with pain were randomly divided into two groups. 50 cases in the control group were treated with routine therapy, and 50 cases in the observation group were treated with ligustrazine injection on this basis. The therapeutic effect, incidence frequency and time of the disease were compared between the two groups. Results: the effective rate of treatment was 94 in the observation group, which was significantly higher than that in the control group (P 0.05), the number of angina pectoris attack and the duration of angina pectoris in the observation group were significantly lower than those in the control group. After treatment, the plasma hypersensitive C-reactive protein (hs-CRPN), lipoprotein associated phospholipase (Lp-PLA2) and cardiac troponin I (cTnI) in the observation group were significantly lower than those in the control group. Conclusion: Ligustrazine is effective in the treatment of unstable angina pectoris, can effectively reduce the attack of angina pectoris, reduce the inflammatory reaction to myocardial injury, improve the ability of myocardial repair, and has positive clinical significance.
【作者单位】：天津市北辰医院检验科;天津市北辰医院心内科;
【基金】：基金项目:天津市北辰区2013-2014科技进步奖(2014-3-14-R2)
【分类号】：R541.4

【相似文献】